<DOC>
	<DOCNO>NCT02561923</DOCNO>
	<brief_summary>The purpose study assess independent effect 4-Factor prothrombin complex concentrate ( PCC ) - ( Kcentra ) Tranexamic acid ( TXA ) bleed parameter ( bleed duration blood volume ) follow punch biopsy , addition assess effect anticoagulant/pharmacodynamic ( prothrombin time endogenous thrombin potential ) change induce rivaroxaban steady state , good understand potential role bleed reversal .</brief_summary>
	<brief_title>A Study Assess Independent Effects 4-Factor Prothrombin Complex Concentrate Tranexamic Acid Bleeding/Pharmacodynamics Healthy Participants</brief_title>
	<detailed_description>This 2 part , single center study conduct healthy men woman . Part 1 ( open-label ) consist Screening Phase ( within 28 day admission study center Day -1 ) , follow 3 day treatment period follow-up visit Day 8 . A single oral 20 milligram ( mg ) dose rivaroxaban administer Day 1 . Pharmacokinetic ( PK ) , pharmacodynamics ( PD ) , punch biopsy parameter assess . Part 2 ( double-blind ) consist Screening Phase ( within 28 day admission study center Day -1 ) , follow 8 day treatment period ( Day -1 Day 7 ) follow-up visit Day 11 . Rivaroxaban ( 20 mg every 12 hr ) administer Days 1 3 single 20 mg dose give morning Day 4 . A single dose either 4-factor PCC , TXA saline ( Placebo ) administer randomize , blinded fashion Day 4 . PK , PD , Exploratory Bio-markers punch biopsy parameter assess . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Protein C</mesh_term>
	<mesh_term>Protein S</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<mesh_term>Thrombin</mesh_term>
	<criteria>Body mass index ( weight kilogram [ kg ] /height^2 meter [ ] ^2 ) 18 30 kg/m2 ( inclusive ) , body weight 50 100 kg ; Participants must coagulation test result prothrombin time ( PT ) partial thromboplastin time ( PTT ) within normal limit Screening Must normal renal function , per medical history If woman , must postmenopausal ( spontaneous menses least 2 year ) , surgically sterile , abstinent , , sexually active , practice effective method birth control ( eg , doublebarrier method male partner sterilization ) entry throughout study . ( Note : combine hormonal contraception use ) Nonsmoker ( Note : subject use nicotinecontaining product within 30 day study drug administration ) If woman , must negative serum Betahuman chorionic gonadotropin ( hCG ) ] pregnancy test Screening ; negative serum pregnancy test Day 1 study If man , must agree use adequate contraception method deem appropriate investigator ( eg , vasectomy , doublebarrier , partner use effective contraception ) donate sperm study 3 month receive last dose study drug History current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease ( include history definite myocardial infarction , cerebrovascular accident , percutaneous transluminal coronary angioplasty coronary artery bypass graft within 6 month Screening visit , previous intracranial hemorrhage time , know history lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , renal hepatic insufficiency , thyroid disease , neurologic psychiatric disease , seizure disorder , infection , skin disease , illness investigator considers exclude subject could interfere interpretation study result Participants history thrombosis , inherit acquire thrombophilia , bleed diathesis coagulopathy ( include abnormal bleeding blood dyscrasia ) , hematologic disease , clinically significant hemorrhagic disorder , excessive bruising , bleed nose gum know disorder increase bleed risk ( eg , acute gastritis , acute peptic ulcer ) , serious bleed include gastrointestinal bleeding require hospitalization , intracranial bleeding type , uncontrollable postoperative bleeding Known antithrombin III , Protein C , Protein S deficiency , Factor V Leiden prothrombin gene 20210 mutation , anticardiolipin ( immunoglobulin G [ IgG ] immunoglobulin M [ IgM ] ) antiphospholipid antibody , family history unexplained thrombotic disorder History intracranial tumor aneurysm know abdominal aneurysm Clinically significant abnormal physical examination , vital sign 12lead electrocardigram [ ECG ] Screening admission study center Day 1 , deem appropriate investigator . This would include : rest pulse &gt; 100 &lt; 40 beat per min , blood pressure systolic &gt; 140 &lt; 90 millimeter per mercuric level [ mmHg ] , diastolic blood pressure &gt; 90 &lt; 50 mmHg ( pulse blood pressure measurement take supine position , rest least 5 minute ) Participants surface blood vessel could visualize , history likelihood form keloid scar Use prescription nonprescription medication ( include antiplatelet , anticoagulant , aspirin , nonsteroidal antiinflammatory drug , vitamin herbal supplement ) , within 7 day first dose study drug schedule Known allergy study drug excipients formulation Unable swallow solid , oral dosage form whole aid water ( participant may chew , divide , dissolve , crush study drug )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Rivaroxaban</keyword>
	<keyword>XARELTO</keyword>
</DOC>